Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, Duygu Tosun, Leslie M. Shaw, Henrik Zetterberg, Jeffrey L. Dage, Kyle Ferber, Gallen Triana-Baltzer, Lei Du-Cuny, Yan Li, Janaky Coomaraswamy, Michael Baratta, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Nicholas J. Ashton, Emily A. Meyers, Carrie E. Rubel, Erin G. Rosenbaugh, Anthony W. Bannon, William Z. Potter, Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team
{"title":"阿尔茨海默病病理学主要血液检测方法的正面比较","authors":"Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, Duygu Tosun, Leslie M. Shaw, Henrik Zetterberg, Jeffrey L. Dage, Kyle Ferber, Gallen Triana-Baltzer, Lei Du-Cuny, Yan Li, Janaky Coomaraswamy, Michael Baratta, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Nicholas J. Ashton, Emily A. Meyers, Carrie E. Rubel, Erin G. Rosenbaugh, Anthony W. Bannon, William Z. Potter, Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team","doi":"10.1002/alz.14315","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Plasma samples from the Alzheimer's Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Plasma p-tau217 measures most accurately classified amyloid and tau status.</li>\n \n <li>Plasma Aβ42/Aβ40 had relatively low accuracy in classification of amyloid status.</li>\n \n <li>Plasma p-tau217 measures had higher correlations with cortical thickness than NfL.</li>\n \n <li>Correlations of plasma biomarkers with dementia symptoms were relatively low.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"20 11","pages":"8074-8096"},"PeriodicalIF":13.0000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14315","citationCount":"0","resultStr":"{\"title\":\"Head-to-head comparison of leading blood tests for Alzheimer's disease pathology\",\"authors\":\"Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, Duygu Tosun, Leslie M. Shaw, Henrik Zetterberg, Jeffrey L. Dage, Kyle Ferber, Gallen Triana-Baltzer, Lei Du-Cuny, Yan Li, Janaky Coomaraswamy, Michael Baratta, Yulia Mordashova, Ziad S. Saad, David L. Raunig, Nicholas J. Ashton, Emily A. Meyers, Carrie E. Rubel, Erin G. Rosenbaugh, Anthony W. Bannon, William Z. Potter, Alzheimer's Disease Neuroimaging Initiative (ADNI) Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer's Disease Project Team\",\"doi\":\"10.1002/alz.14315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> INTRODUCTION</h3>\\n \\n <p>Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>Plasma samples from the Alzheimer's Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Plasma p-tau217 measures most accurately classified amyloid and tau status.</li>\\n \\n <li>Plasma Aβ42/Aβ40 had relatively low accuracy in classification of amyloid status.</li>\\n \\n <li>Plasma p-tau217 measures had higher correlations with cortical thickness than NfL.</li>\\n \\n <li>Correlations of plasma biomarkers with dementia symptoms were relatively low.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"20 11\",\"pages\":\"8074-8096\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2024-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.14315\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.14315\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.14315","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Head-to-head comparison of leading blood tests for Alzheimer's disease pathology
INTRODUCTION
Blood tests have the potential to improve the accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.
METHODS
Plasma samples from the Alzheimer's Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.
RESULTS
Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.
DISCUSSION
This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.
Highlights
Plasma p-tau217 measures most accurately classified amyloid and tau status.
Plasma Aβ42/Aβ40 had relatively low accuracy in classification of amyloid status.
Plasma p-tau217 measures had higher correlations with cortical thickness than NfL.
Correlations of plasma biomarkers with dementia symptoms were relatively low.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
